Management Forum Logo

Presented by
Management Forum

Delivery of Biologics to the Nasal Cavity In-house Training

The Future of Nasal Drug Delivery

The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. This is an ideal opportunity to hear from experts in the field of nasal drug delivery who will address topics such as: challenges associated with formulation, barriers to cell penetration and absorption, the pros and cons for liquid versus powder formulations, and strategies for maintaining stability and prolonging retention in the nasal cavity.

★★★★★ "Very clear and informative!"

Need help? 

Overview

The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. For example, an intranasal mAb formulation is in phase 1 clinical trials for progressive Multiple Sclerosis.

This course will address the challenges associated with formulation and clinical trial manufacture of biologics for delivery to the nasal cavity. The course will also highlight barriers to cell penetration and absorption and identification of an ideal target product profile.

The pros and cons for liquid versus powder formulations will be discussed. In addition, the course will focus on strategies for maintaining stability and prolonging retention in the nasal cavity. Device selection for preclinical and clinical studies using predictive tools such as nasal casts will be presented.

Finally, the session will help prepare the audience with manufacturing strategies for clinical trials with a nasally administered biologic.

This course is of our range of Medical Devices training courses - now also including Medical Devices Cyber Security training to help improve your data security.

Who Should Attend

  • Research and Development
  • Formulation Development
  • Clinical Development
  • CMC Managers
  • Program Management
  • Development Engineers
  • Clinical Trial Manufacturing

This course will cover:

Challenges and Opportunities

  • Define biologics scope
  • Overcoming barriers
  • Device selection
  • Targeted delivery in the nose
  • Liquid vs powder formulations

Julie Suman, Aptar Pharma

Formulation Strategies

  • Stabilizing biologics
  • Formulation strategies
  • Identify CQA and TPP
  • Case studies

David Farrow, Aptar Pharma

Analytical Considerations for Nasally Delivery Biologics

  • Considerations with compendial analysis for nasal products
  • Secondary structure and aggregate analysis
  • Modeling of deposition using nasal casts
  • Device impact on the formulation

Lucas Silva, Nanopharm

How to Get Ready for a Clinical Trial with a Biologic

  • Specification setting
  • Drug product manufacturing
  • Drug product release testing and stability studies
  • Regulatory considerations

Gemma Budd, Nanopharm

Q & A Discussion

Reviews of IPI's Delivery of Biologics to the Nasal Cavity training course


Very clear and informative!

Oct 10 2023

Serge PAMPFER
CEO, Maedia

Jun 6 2023

The webinar was an excellent overview and insight into an emerging field - good balance of market intel and technical detail.

Eleanor Catherine Canipa
Senior Business Development Manager, Nanopharm (an Aptar Company)

United States of America

  • Aptar Pharma
  • Aptargroup Inc.
  • HDT Bio Corp.
  • IGM Biosciences
  • Lonza
  • NA
  • Pace Life Sciences
  • Proveris
  • Renaissance Lakewood, LLC
  • Renaissance Lakewood, LLC.
  • Rhino Systems Inc
  • SGD Pharma Packaging
  • Summit Biosciences

United Kingdom

  • LABORATORIES HIPRA SA
  • Malvern Panalytical
  • Nanopharm
  • Nanopharm (an Aptar Company)
  • Proveris Scientific Corporation
  • Therakind Limited

Israel

  • Formulex Pharma Innovations
  • Padagis
  • Padagis Israel Pharmaceuticals
  • Sever lufe science

Italy

  • Chiesi Farmaceutici S.p.A.
  • Chiesi Farmaceutici SpA
  • Stevanato Group

Argentina

  • Aptar
  • Aptar Pharma

Germany

  • Aptar CSP Technologies
  • URSATEC GmbH

Sweden

  • GRP Consulting AB
  • Orexo AB

Australia

  • MONASH UNIVERSITY

Belgium

  • Maedia

Canada

  • Apotex Inc.

Denmark

  • ALK-Abello A/S

Switzerland

  • TRB Chemedica

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Yesim NURKO
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy